Minerva Neurosciences investor relations material

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. The company is developing brexanolone (MNRX), which targets all three types of glucocorticoid receptors to treat postpartum depression and infantile spasms in children. It also focuses on the research and development of a pipeline of compounds that modulate GABA receptors or downstream pathways and programs targeting other neurotransmitter systems. Minerva Neurosciences was founded in 2009 and is based in Menlo Park, California.